Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
2023年12月8日 - 6:05AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced the
initial LUNA preliminary efficacy and safety data will be presented
at the upcoming 47th Annual Meeting of the Macula Society, being
held February 7 – 10, 2024.
“We are very pleased to have the opportunity to present our
initial Phase 2 efficacy and safety data from the LUNA study at the
Macula Society meeting” stated Laurent Fischer, M.D., president and
chief executive officer of Adverum Biotechnologies. “We recently
received confirmation that our abstract was accepted and we are
delighted to present at a medical conference focused on
groundbreaking advances in retinal and macular diseases. We look
forward to sharing those data during the meeting in early February
rather than before year end, as originally planned.”
Macula Society Meeting Presentation
Details:
Title: Ixoberogene soroparvovec (Ixo-vec)
Intravitreal Gene Therapy for Neovascular Age-Related Macular
Degeneration: Preliminary Results from the Phase 2 LUNA Study
Date / Time: Thursday, February 8th, 2024 at
7:56 am PT*
Session: AMD II Neovascular Trials
Presenter: Arshad M. Khanani, M.D., M.A.,
FASRS, Director of Clinical Research at Sierra Eye Associates,
Clinical Associate Professor at University of Nevada, Reno School
of Medicine
Adverum Biotechnologies plans to host a conference call to
discuss these data, with details to be provided at a future date.
The presentation from the 47th Annual Macula Society Meeting will
also be made available on Adverum’s website under News &
Publications and through the following link:
https://adverum.com/news-publications.
*Preliminary schedule with the exact date and time of
presentation subject to change.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy candidate,
ixoberogene soroparvovec (Ixo-vec, formerly referred to as
ADVM-022), as a one-time, IVT injection for patients with
neovascular or wet age-related macular degeneration. Additionally,
by overcoming the challenges associated with current treatment
paradigms for debilitating ocular diseases, Adverum aspires to
transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Forward-looking Statements Statements contained
in this press release regarding events or results that may occur in
the future are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements include but are not limited to statements regarding the
anticipated release of initial preliminary efficacy and safety data
from the LUNA trial. Actual results could differ materially from
those anticipated in such forward-looking statements as a result of
various risks and uncertainties, including risks inherent to,
without limitation: Adverum’s novel technology, which makes it
difficult to predict the timing of commencement and completion of
clinical trials; regulatory uncertainties; enrollment
uncertainties; the results of early clinical trials not always
being predictive of future clinical trials and results; and the
potential for future complications or side effects in connection
with use of Ixo-vec. Additional risks and uncertainties facing
Adverum are set forth under the caption “Risk Factors” and
elsewhere in Adverum’s Securities and Exchange Commission (SEC)
filings and reports, including Adverum’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2023 filed with the SEC on
November 9, 2023. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Adverum undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Inquiries: Adverum Investor RelationsEmail:
ir@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
過去 株価チャート
から 5 2024 まで 6 2024
Adverum Biotechnologies (NASDAQ:ADVM)
過去 株価チャート
から 6 2023 まで 6 2024